Cardiol Therapeutics (CRDL) Projected to Post Earnings on Monday

Posted by Tristan Rich on Apr 18th, 2025

Cardiol Therapeutics (NASDAQ:CRDL – Get Free Report) is expected to be announcing its earnings results before the market opens on Monday, April 21st. Analysts expect the company to announce earnings of ($0.09) per share for the quarter.

Cardiol Therapeutics (NASDAQ:CRDL – Get Free Report) last announced its quarterly earnings data on Monday, March 31st. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01. On average, analysts expect Cardiol Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cardiol Therapeutics Stock Performance

Shares of Cardiol Therapeutics stock opened at $1.01 on Friday. The firm’s 50 day moving average is $1.08 and its 200 day moving average is $1.40. The firm has a market capitalization of $83.44 million, a PE ratio of -2.59 and a beta of 1.00. Cardiol Therapeutics has a 1 year low of $0.77 and a 1 year high of $3.12. The company has a current ratio of 2.49, a quick ratio of 2.49 and a debt-to-equity ratio of 0.01.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. HC Wainwright restated a “buy” rating and set a $9.00 price target on shares of Cardiol Therapeutics in a report on Wednesday. RODMAN&RENSHAW upgraded shares of Cardiol Therapeutics to a “strong-buy” rating in a research report on Tuesday, January 28th. Finally, Rodman & Renshaw initiated coverage on shares of Cardiol Therapeutics in a report on Tuesday, January 28th. They set a “buy” rating and a $7.00 price target on the stock. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Cardiol Therapeutics has a consensus rating of “Buy” and a consensus price target of $8.40.

Get Our Latest Stock Analysis on Cardiol Therapeutics

About Cardiol Therapeutics

(Get Free Report)

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.